Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA281071
Max Phase: Preclinical
Molecular Formula: C14H22O
Molecular Weight: 206.33
Molecule Type: Small molecule
Associated Items:
ID: ALA281071
Max Phase: Preclinical
Molecular Formula: C14H22O
Molecular Weight: 206.33
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)(C)c1cccc(C(C)(C)C)c1O
Standard InChI: InChI=1S/C14H22O/c1-13(2,3)10-8-7-9-11(12(10)15)14(4,5)6/h7-9,15H,1-6H3
Standard InChI Key: DKCPKDPYUFEZCP-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: Yes | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 206.33 | Molecular Weight (Monoisotopic): 206.1671 | AlogP: 3.99 | #Rotatable Bonds: 0 |
Polar Surface Area: 20.23 | Molecular Species: NEUTRAL | HBA: 1 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 1 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.26 | CX Basic pKa: | CX LogP: 4.76 | CX LogD: 4.76 |
Aromatic Rings: 1 | Heavy Atoms: 15 | QED Weighted: 0.68 | Np Likeness Score: -0.03 |
1. James R, Glen JB.. (1980) Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents., 23 (12): [PMID:7452689] [10.1021/jm00186a013] |
2. Krasowski MD, Hong X, Hopfinger AJ, Harrison NL.. (2002) 4D-QSAR analysis of a set of propofol analogues: mapping binding sites for an anesthetic phenol on the GABA(A) receptor., 45 (15): [PMID:12109905] [10.1021/jm010461a] |
3. Selassie CD, Kapur S, Verma RP, Rosario M.. (2005) Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study., 48 (23): [PMID:16279782] [10.1021/jm050567w] |
4. Sentürk M, Gülçin I, Daştan A, Küfrevioğlu OI, Supuran CT.. (2009) Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols., 17 (8): [PMID:19231207] [10.1016/j.bmc.2009.01.067] |
5. PubChem BioAssay data set, |
6. PubChem BioAssay data set, |
7. Cioffi CL.. (2018) Modulation of Glycine-Mediated Spinal Neurotransmission for the Treatment of Chronic Pain., 61 (7): [PMID:28876062] [10.1021/acs.jmedchem.7b00956] |
Source(2):